Prophylactic surgery rates among men with breast cancer nearly double
the ONA take:
The rates of contralateral prophylactic mastectomy (CPM) among men with breast nearly doubled between 2004 and 2011, which mirrors a trend seen in women with breast cancer, according to a report from American Cancer Society and Dana Farber Cancer Institute researchers.
In women, particularly younger women, use of CPM has increased over the past two decades despite a lack of evidence for survival benefit, associated costs, and possible complications. Breast cancer in men accounts for approximately 1% of all cases in the United States.
The researchers pulled nationwide data from the North American Association of Central Cancer Registries on 6,332 men who underwent surgery for breast cancer limited to one breast between 2004 and 2011.
Rate of CMP among men increased from 3.0% in 2004 to 5.6% in 2011. The sociodemographic factors linked to more surgery in men were similar to those for women who underwent CPM: being white, younger age, and having private insurance.
However, the study did not have data on other factors linked to women who choose to undergo CPM, such as genetic testing, family history, magnetic resonance imaging, or fear of breast cancer occurring in the other breast.
The rates of contralateral prophylactic mastectomy (CPM) among men with breast nearly doubled between 2004 and 2011.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|